RETRACTED: Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease(Retracted article.See vol.87,pg.239,2016)

Background: There is a high incidence of hip fractures in patients with Parkinson disease ( PD). Bone mineral density ( BMD) is decreased in patients with PD, correlating with the immobilization- induced bone resorption and hypovitaminosis D with compensatory hyperparathyroidism. Objective: To evaluate the effectiveness of risedronate, an inhibitor of bone resorption, on osteoporosis and the risk of hip fractures in elderly men with PD. Methods: This was a 2- year, randomized, double- blind, placebo- controlled trial. In a prospective study of patients with PD, 121 patients received a daily dose of 2.5 mg risedronate and vitamin D2 1,000 IU for 2 years, and the remaining 121 received placebo and vitamin D2 1,000 IU. Incidence of hip fractures was compared between the two groups. Results: Nine patients sustained hip fractures in the placebo group, and three hip fractures occurred in the risedronate group. The relative risk of a hip fracture in the risedronate group vs the placebo group was 0.33 ( 95% CI, 0.09 to 1.20). BMD increased by 2.2% in the risedronate group and decreased by 2.9% in the placebo group ( p < 0.0001). Urinary deoxypyridinoline, a bone resorption marker, decreased by 46.7% in the risedronate group and by 33.0% in the placebo group. Conclusion: Treatment with risedronate and vitamin D2 increases bone mineral density in elderly men with Parkinson disease and reduces the risk of hip fractures.